<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879810</url>
  </required_header>
  <id_info>
    <org_study_id>15.0872</org_study_id>
    <nct_id>NCT04879810</nct_id>
  </id_info>
  <brief_title>Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease</brief_title>
  <official_title>Pilot Clinical Trial Investigating the Ability of Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (IBD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will test the hypothesis that edible structures within plant cells (ginger) will&#xD;
      have clinically important anti-inflammatory effects on the gut lining of patients with&#xD;
      inflammable bowel disease.&#xD;
&#xD;
      To evaluate the safety and tolerability of exosomes with and without curcumin in patients&#xD;
      with Inflammatory Bowel Disease (IBD); To estimate the effect of ginger exosomes or curcumin&#xD;
      alone or combined with curcumin on the symptoms and disease score in patients with refractory&#xD;
      IBD describe toxicities associated with ginger exosomes; to evaluate the effect of ginger&#xD;
      exosomes on biomarkers of inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 90 patients with Chronic IBD will be enrolled, with the goal of having three arms of 30&#xD;
      subjects in each group who are eligible for evaluation.&#xD;
&#xD;
      This exploratory trial is designed to estimate the effect of ginger exosomes or curcumin on&#xD;
      IBD symptoms compared to ginger exosomes plus curcumin. In this prospective and randomized&#xD;
      study the main focus is to compare exosomes alone, curcumin, and exosomes plus curcumin.&#xD;
      Three primary stratification factors race (white and black), gender and type of IBD (CD and&#xD;
      UC) will be used. plan Zelen's (1974) method will be used to avoid imbalance allocation&#xD;
      within each stratum. A block size of 4 will be used. We plan to enroll all eligible patients&#xD;
      visiting the clinic, as well as eligible patients referred from other gastroenterologists.&#xD;
      All eligible visiting our clinic will be enrolled. By enrolling consecutive patients, we&#xD;
      reduce selection bias. A patient will be enrolled only once.&#xD;
&#xD;
      The most important aim of this study is to compare the IBD symptoms in exosomes alone and&#xD;
      exosomes plus curcumin groups of patients. The symptomatology will be measured in each group&#xD;
      and compared to the self-reported score. We will use the incidence rate of bloody stool to&#xD;
      justify the sample size. With the combination treatment (ginger exosomes plus curcumin as&#xD;
      compared to curcumin alone) we hope to reduce symptoms by at least 30%. Using a two sample&#xD;
      one-sided t test for comparing mean differences in Inflammatory Bowel Disease Questionnaire,&#xD;
      with 30 subjects in each group and using alpha=5%, we will have 80% power to detect effect&#xD;
      size of 0.65 Standard Deviation, which is a large effect size (Cohen, 1988).. When the&#xD;
      reduction in sample size due to missing data or other reasons, we will have reduced power to&#xD;
      detect the difference in two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>three Arms: 1. Ginger exosomes;2. Curcumin; 3. Ginger exosomes plus curcumin, Each PO daily times 28 days. All subjects will receive active treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammation on Colonoscopy</measure>
    <time_frame>30 days</time_frame>
    <description>Decrease in inflammatory cells in the biopsy after treatment versus before treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Subjective symptoms</measure>
    <time_frame>30 days</time_frame>
    <description>Questionnaire reporting of decrease in subjective symptoms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Irritable Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Ginger exosomes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ginger exosomes plus curcumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study mixture will be taken PO daily times 28 days Sigmoidoscopy and biopsy, blood work, quality of life questionnaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sigmoidoscopy and biopsy, blood work</intervention_name>
    <description>Flexible tube up lower colon, blood draws, quality of life questionnaires</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Ginger exosomes</arm_group_label>
    <arm_group_label>Ginger exosomes plus curcumin</arm_group_label>
    <other_name>Inflammatory Bowel Disease Questionnaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a confirmed diagnosis of IBD (either CD or UC) with moderate&#xD;
             disease activity.)&#xD;
&#xD;
          -  Ability to independently care for oneself&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known HIV&#xD;
&#xD;
          -  Patients receiving immunosuppressive drugs, other than for their bowel disease&#xD;
&#xD;
          -  Patients must be on stable doses of their medications for the 2 weeks prior to study&#xD;
             entry and for the duration of the treatment period, or inform the investigator of any&#xD;
             changes in medication&#xD;
&#xD;
          -  Active malignancy in the last 5 years&#xD;
&#xD;
          -  Patients receiving any other investigational agent(s)&#xD;
&#xD;
          -  Ginger allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Galandiuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Trachtenberg</last_name>
    <phone>5028521671</phone>
    <email>lstrac01@louisville.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Galandiuk, MD</last_name>
    <phone>5028524568</phone>
    <email>s0gala01@exchange.louisville.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Trachtenberg</last_name>
      <phone>502-852-1671</phone>
      <email>lstrac01@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Galandiuk, MD</last_name>
      <phone>5028524568</phone>
      <email>s0gala01@exchange.louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Galandiuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zhang M, Viennois E, Prasad M, Zhang Y, Wang L, Zhang Z, Han MK, Xiao B, Xu C, Srinivasan S, Merlin D. Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016 Sep;101:321-40. doi: 10.1016/j.biomaterials.2016.06.018. Epub 2016 Jun 9.</citation>
    <PMID>27318094</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Susan Galandiuk</investigator_full_name>
    <investigator_title>Principal Investigator and Director, Division of Colorectal Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

